Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Gonadorelin

GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel

Quick Stats
Studies 192
Trials 100
Completed NA INTERVENTIONAL NCT05473039

Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study evaluates the effect of pretreatment with a multivitamin supplement with probiotics (Seidivid Ferty4®) on oocyte retrieval in normo-responder patients undergoing controlled ovarian hyperstimulation (COH) for oocyte donation, considering both the total number of oocytes retrieved and the number of mature oocytes retrieved, that is, in metaphase II (MII).

Detailed Description

Patients will be recruited on the day they are going to start the egg donation program. The patient will start taking the study treatment (multivitamin supplement with probiotics or placebo) immediately after inclusion and will call the site to initiate the oocyte donation protocol approximately 30 days after enrollment. Throughout the COH period of the protocol the patient will continue taking the study supplement (or placebo), without interruption until the day of the GnRH-agonist trigger. The administration of the agonist will be as a single dose, 36 hours before follicular puncture for the retrieval of mature eggs. Then, the retrieved oocytes will be denuded and examined by light microscopy to assess their quality. The evaluation will carried out by two different embryologists, blinded to the study protocol.

Interventions

Name: Seidivid Ferty4
Type: DIETARY_SUPPLEMENT
Description: The patient will start taking the study treatment (multivitamin supplement with probiotics) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the diatary supplement, without interruption until the day of the GnRH-agonist trigger.
Name: Placebo
Type: OTHER
Description: The patient will start taking the study treatment (placebo) immediately after inclusion. Throughout the COH period of the protocol (usual mean duration: 11 days) the patient will continue taking the treatment (placebo), without interruption until the day of the GnRH-agonist trigger.

Primary Outcomes

Measure: Number of Oocytes Retrieved
TimeFrame: Through study completion, an average of 42 days
Description: Total number of oocytes retrieved in the follicular puncture
Measure: Number of Mature (MII) Oocytes Retrieved
TimeFrame: Through study completion, an average of 42 days
Description: Total number of mature oocytes (metaphase II, or MII) retrieved in the follicular puncture

Trial Information

NCT ID

NCT05473039

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

SEID S.A.

Last Updated

December 15, 2025